Literature DB >> 31693093

Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry.

Tosho Balabanski1, Josep Brugada2, Elena Arbelo3, Cécile Laroche4, Aldo Maggioni4,5, Carina Blomström-Lundqvist6, Josef Kautzner7, Luigi Tavazzi8, Massimo Tritto9, Piotr Kulakowski10, Oskars Kalejs11, Tamas Forster12, Federico Segura Villalobos13, Nikolaos Dagres14.   

Abstract

AIMS: Monitoring of patients after ablation had wide variations in the ESC-EHRA atrial fibrillation ablation long-term (AFA-LT) registry. We aimed to compare four different monitoring strategies after catheter AF ablation. METHODS AND
RESULTS: The ESC-EHRA AFA-LT registry included 3593 patients who underwent ablation. Arrhythmia monitoring during follow-up was performed by 12-lead electrocardiogram (ECG), Holter ECG, trans-telephonic ECG monitoring (TTMON), or an implanted cardiac monitoring (ICM) system. Patients were selected to a given monitoring group according to the most extensive ECG tool used in each of them. Comparison of the probability of freedom from recurrences was performed by censored log-rank test and presented by Kaplan-Meier curves. The rhythm monitoring methods were used among 2658 patients: ECG (N = 578), Holter ECG (N = 1874), TTMON (N = 101), and ICM (N = 105). A total of 767 of 2658 patients (28.9%) had AF recurrences during follow-up. Censored log-rank test discovered a lower probability of freedom from relapses, which was detected with ICM compared to TTMON, ECG, and Holter ECG (P < 0.001). The rate of freedom from AF recurrences was 50.5% among patients using the ICM while it was 65.4%, 70.6%, and 72.8% using the TTMON, ECG, and Holter ECG, respectively.
CONCLUSION: Comparing all main electrocardiographic monitoring methods in a large patient sample, our results suggest that post-ablation recurrences of AF are significantly underreported by TTMON, ECG, and Holter ECG. The ICM estimates AF ablation recurrences most reliably and should be a preferred mode of monitoring for trials evaluating novel AF ablation techniques. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Ablation; Atrial fibrillation; EHRA registry; Recurrence; Rhythm monitoring

Year:  2019        PMID: 31693093     DOI: 10.1093/europace/euz216

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  4 in total

1.  Cryoballoon Catheter Ablation in Korean Patients With Paroxysmal and Persistent Atrial Fibrillation: One Year Outcome From the Cryo Global Registry.

Authors:  Hong Euy Lim; Il-Young Oh; Fred J Kueffer; Kelly Anna van Bragt; Young Keun On
Journal:  Korean Circ J       Date:  2022-08-12       Impact factor: 3.101

2.  Healthcare utilization and clinical outcomes after ablation of atrial fibrillation in patients with and without insertable cardiac monitoring.

Authors:  Moussa C Mansour; Emily M Gillen; Audrey Garman; Sarah C Rosemas; Noreli Franco; Paul D Ziegler; Jesse M Pines
Journal:  Heart Rhythm O2       Date:  2022-01-07

3.  Posterior wall isolation in persistent atrial fibrillation feasibility, safety, durability, and efficacy.

Authors:  René Worck; Samuel K Sørensen; Arne Johannessen; Martin Ruwald; Martin Haugdal; Jim Hansen
Journal:  J Cardiovasc Electrophysiol       Date:  2022-05-31       Impact factor: 2.942

4.  Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial.

Authors:  Shouvik Haldar; Habib Rehman Khan; Vennela Boyalla; Ines Kralj-Hans; Simon Jones; Joanne Lord; Oluchukwu Onyimadu; Anitha Satishkumar; Toufan Bahrami; Anthony De Souza; Jonathan R Clague; Darrel P Francis; Wajid Hussain; Julian W Jarman; David Gareth Jones; Zhong Chen; Neeraj Mediratta; Jonathan Hyde; Michael Lewis; Raad Mohiaddin; Tushar V Salukhe; Caroline Murphy; Joanna Kelly; Rajdeep S Khattar; William D Toff; Vias Markides; James McCready; Dhiraj Gupta; Tom Wong
Journal:  Eur Heart J       Date:  2020-12-14       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.